- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03832023
Community-based Tuberculosis Tracing and Preventive Therapy (CONTACT)
Community Intervention for Tuberculosis Active Contact Tracing and Preventive Therapy - a Cluster Randomized Study (CONTACT)
The many gaps observed in the cascade of care of tuberculosis (TB) child contacts occur mostly in the screening, preventive therapy (PT) initiation and PT completion steps and the main drivers of these gaps are considered to be the health system infrastructure, limited worker resources and parents' reluctance to bring their children to the facility for screening. There would be great advantages of using a symptom-based screening at community level where only the symptomatic contacts are referred to hospital for further evaluation and asymptomatic contacts are started on PT in the community. Household or community-based screening is likely to improve the uptake and acceptability of child contact screening and management as well as adherence to PT and to reduce cost and workload at facility level.
This study proposes to compare the cascade of care between two models for TB screening and management of household TB child contacts in two high TB burden and limited resource countries, Cameroon and Uganda. In the facility-based model, children will be screened at facility (Cameroon) or household level (Uganda) and preventive therapy initiation, refills of PT therapy and follow-up will be done at facility level. In the intervention group (community-based model), child contacts will be screened in the household by a community health worker (CHW). Those with symptoms suggestive of TB will be referred to the facility for TB investigations. Asymptomatic child contacts from high risk groups (under-5 years or HIV infected 5-14) will be initiated on PT (3 months isoniazid-rifampicin) in the household. Refills of PT therapy will also be done in the communities by the CHW. In both models, symptomatic children requiring further investigations for TB diagnosis will be referred to a health facility.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary study objective is to compare the proportion of household child TB contacts eligible for PT (under-5 years and HIV-infected children 5-14 years without active TB) who initiate and complete PT using facility-based and decentralized community-based models of care for contact screening and management.
Secondary objectives are:
To compare the facility and community-based models in terms of:
- The full cascade of care for the initiation and completion of PT in child TB contacts < 5 years or HIV+ children 5-14 years .
- Cascade of care for the detection and treatment of TB in child contacts (all ages):
- PT tolerability and adherence among eligible child contacts initiated on PT.
- Treatment uptake and outcomes for child contacts diagnosed with TB .
- Child contact outcomes at 6 months after enrollment for all child contacts.
- Acceptability by the parents/guardians, health personnel and community of the different models of care.
- Cost and cost-effectiveness of the different models.
- Fidelity of the implementation of the model activities as compared to the protocol.
- To assess the number of adult contact cases diagnosed with TB through the community-based screening.
To compare between the pre- (baseline assessment) and post-intervention (by model of care) data related to:
- Children diagnosed with TB and registered at facility level and their treatment outcome.
- Adults diagnosed with TB and registered at facility level and their treatment outcome.
- PT initiation and outcomes.
This study will be implemented under the frame of the Catalyzing Pediatric TB Innovation (CaP TB) Project, funded by Unitaid and implemented by the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF). The goal of CaP TB is to improve the pediatric TB morbidity and mortality by catalyzing the wide uptake of the new first-line fixed dose combination drugs for children and optimizing the use of these drugs through improved case detection and innovative models of care. In both models of care, contacts with TB suggestive symptoms will be investigated for TB at the cluster facility that is supported by EGPAF within the CaP TB project. In Cameroon the CaP TB project will be implemented in the Central and Littoral regions and in Uganda in the South-West region.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bonabéri, Cameroon
- Hôpital de district Bonassama
-
Douala, Cameroon
- Hôpital de district Log-Baba
-
Edéa, Cameroon
- Centre Médical d'arrondissement Delangue
-
Mbalmayo, Cameroon
- Hôpital de district Mbalmayo
-
Mfou, Cameroon
- Hôpital de district Mfou
-
Nkongsamba, Cameroon
- Hôpital régional Nkongsamba
-
Okola, Cameroon
- Hôpital de district Okola
-
Olembe, Cameroon
- Hôpital de district Olembe
-
Penja, Cameroon
- Hôpital de district St Jean de Malte
-
Yoko, Cameroon
- Hôpital de district Yoko
-
-
-
-
-
Ibanda, Uganda
- Ishongororo HC IV
-
Ibanda, Uganda
- Ruhoko HC IV
-
Kabwohe, Uganda
- Kabwohe Clinical Research Center HC II
-
Kabwohe, Uganda
- Kabwohe HC IV
-
Kitagata, Uganda
- Kitagata Hospital
-
Mbarara, Uganda
- Bubaare HC III
-
Mbarara, Uganda
- Bwizibwera HC IV
-
Mbarara, Uganda
- Kakoba HC III
-
Mbarara, Uganda
- Mbarara Municipal Council HC IV
-
Ntungamo, Uganda
- Bwongyera HC III
-
Ntungamo, Uganda
- Itojo Hospital
-
Ntungamo, Uganda
- Kitwe HC IV
-
Ntungamo, Uganda
- Ntungamo Ngoma HC III
-
Ntungamo, Uganda
- Rubaare HC IV
-
Ntungamo, Uganda
- Rwashamaire HC IV
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Inclusion of the index cases
- Age > 15 years
- Newly bacteriologically confirmed TB case (less than a month since diagnosis)
- Reports child contact(s)
- Written informed consent signed by the index case and by parents/guardians for minors or incapacitated people
Inclusion of contacts
- Household contact
- Age
- Facility-based model in Cameroon: < 5 years or HIV infected 5-14 years and all self-referred adults or children*.
- Facility-based model in Uganda and community-based model on both countries: all ages
- Written informed consent signed by adult contacts and by parents/guardians for minors or incapacitated people
- Written assent for children > 7 years in Cameroon and ≥8 years in Uganda
Under the facility-based model in Cameroon, although there is no systematic request to screen adults or HIV-negative child contacts 5-14 years old, first inclusions showed that some of them came by themselves for TB screening. This justifies their inclusion in the study in order to ensure the completeness of data for all contacts screened under the facility-based model.
Exclusion Criteria:
- Exclusion of index cases
- Index cases who do not have child household contacts living in the catchment area of one of the study clusters
- Index cases diagnosed with rifampicin resistance, multidrug-resistant (MDR) or extensively drug-resistant (XDR) TB *Index cases from a household screened within the CONTACT study and that does not declare child contacts from another household.*
- Index cases that are prisoners
TB confirmed adult contacts cases living in the same household as an index case already enrolled in the study will not be included as new index cases unless they declare additional contacts from another household
- Exclusion of the contacts
- If the contact is already on PT or on TB treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Facility-based model
Standard of care of each country
|
|
|
Experimental: Community-based model
Screening and initiating preventive therapy in communities
|
Symptom-based screening of tuberculosis household child contacts by community health workers; initiation of preventive therapy (3 months of a fixed-dose combination of rifampicin-isoniazid or 6 months isoniazid for HIV+ children on protease inhibitors) in the household by a nurse; follow-up of children under preventive therapy by a community health worker for eligible children at community level, and referral of presumptive tuberculosis cases (children and adults) to the facility.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Completion of preventive therapy
Time Frame: 6 months
|
Proportion of child TB contacts <5 years of age and HIV-infected children of 5-14 years of age who initiate and complete the PT of all child contacts <5 years of age and HIV-infected children of 5-14 years of age declared by the index case
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of children eligible for PT
Time Frame: 6 months
|
Number of children eligible for PT among screened children
|
6 months
|
|
Proportion of children started on PT
Time Frame: 6 months
|
Number of children started on PT among those eligible for PT
|
6 months
|
|
Proportion of children who did not complete PT
Time Frame: 6 months
|
Number of children who did not complete PT among those started on PT
|
6 months
|
|
Proportion of children investigated for TB
Time Frame: 1 month
|
Number of children with presumptive TB investigated for TB
|
1 month
|
|
Proportion of children diagnosed with TB
Time Frame: 1 month
|
Number of children diagnosed with TB among those with symptoms suggestive of TB
|
1 month
|
|
Proportion of children started on TB treatment
Time Frame: 1 month
|
Number of children with TB diagnosis who are started on TB treatment
|
1 month
|
|
Proportion of adult contacts screened
Time Frame: 1 month
|
Number of adult contacts screened among household identified adult contacts
|
1 month
|
|
Proportion of adults presumptive TB cases
Time Frame: 1 month
|
Number of adults with symptoms suggestive of TB among those screened for TB
|
1 month
|
|
Proportion of adults diagnosed with TB
Time Frame: 1 month
|
Number of adults presumptive TB cases diagnosed with TB
|
1 month
|
|
Proportion of children with serious adverse events
Time Frame: 6 months
|
Number of children with serious adverse events among children started on PT
|
6 months
|
|
Proportion of children with adverse event of interest
Time Frame: 6 months
|
Number of children with adverse event of interest (peripheral neuropathy, clinical hepatotoxicity) among children on PT
|
6 months
|
|
Treatment adherence
Time Frame: 6 months
|
Ratio of PT dose taken by the child over the total number of doses prescribed
|
6 months
|
|
Treatment outcomes of children started on TB treatment
Time Frame: 6 months
|
|
6 months
|
|
Proportion of children diagnosed with TB
Time Frame: 6 months
|
Number of children diagnosed with TB after initiation of PT or children not initiated on PT and not diagnosed with TB at baseline
|
6 months
|
|
TB case detection during pre-intervention period
Time Frame: 2 years
|
Number of patients registered in the facility TB register one year before intervention
|
2 years
|
|
Proportion of children among all registered TB cases during pre-intervention period
Time Frame: 2 years
|
Number of children among all patients diagnosed with TB and registered in the facility TB register one year before intervention
|
2 years
|
|
TB treatment outcome of registered TB patients during pre-intervention period
Time Frame: 2 years
|
|
2 years
|
|
Number of children started on PT during pre-intervention period
Time Frame: 2 years
|
Number of children started on PT from the facility PT register one year before intervention
|
2 years
|
|
Completion rate of children started on PT intervention during pre-intervention period
Time Frame: 2 years
|
Number of children who completed PT among those started on PT from the facility PT register one year before
|
2 years
|
|
Number of household visits by CHW
Time Frame: 2 years
|
Number of visits by the CHW to the household for contact screening per household
|
2 years
|
|
Proportion of parents/guardians who accept household visit
Time Frame: 2 years
|
Acceptability of household visit for contact screening
|
2 years
|
|
Reasons of refusal of household visit
Time Frame: 2 years
|
Description of screening failures
|
2 years
|
|
Preference for household visit versus facility visit
Time Frame: 2 years
|
This outcome measures whether the parent/guardian prefers bringing child to the facility rather than having someone coming to his household
|
2 years
|
|
Critical events experienced by CHW during household visit
Time Frame: 2 years
|
Description of critical events during house visit and how these where dealt with
|
2 years
|
|
Transport cost for household visit by CHW
Time Frame: 2 years
|
Cost of transportation for the CHW to go from the health facility to a household
|
2 years
|
|
Transport cost for parents/guardian for facility-based screening
Time Frame: 2 years
|
Cost supported by families to bring child contact to the facility for screening
|
2 years
|
|
Time spent to perform household contact screening visit
Time Frame: 2 years
|
It includes the time to reach the household, the time spent in the household and the time to go back to the facility for CHW
|
2 years
|
|
Proportion of delivered activities compared to the intended activities of the model
Time Frame: 2 years
|
This outcome will assess fidelity to study procedures
|
2 years
|
|
Proportion of children screened
Time Frame: 6 months
|
Number of children screened among child contacts <5 years or HIV-infected 5-14 years declared by the index case
|
6 months
|
|
Proportion of children with presumptive TB
Time Frame: 1 month
|
Number of children with symptoms suggestive of TB among screened children (< 15 years)
|
1 month
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Mandalakas AM, Kirchner HL, Walzl G, Gie RP, Schaaf HS, Cotton MF, Grewal HM, Hesseling AC. Optimizing the detection of recent tuberculosis infection in children in a high tuberculosis-HIV burden setting. Am J Respir Crit Care Med. 2015 Apr 1;191(7):820-30. doi: 10.1164/rccm.201406-1165OC.
- Rutherford ME, Hill PC, Triasih R, Sinfield R, van Crevel R, Graham SM. Preventive therapy in children exposed to Mycobacterium tuberculosis: problems and solutions. Trop Med Int Health. 2012 Oct;17(10):1264-73. doi: 10.1111/j.1365-3156.2012.03053.x. Epub 2012 Aug 5.
- Triasih R, Robertson CF, Duke T, Graham SM. A prospective evaluation of the symptom-based screening approach to the management of children who are contacts of tuberculosis cases. Clin Infect Dis. 2015 Jan 1;60(1):12-8. doi: 10.1093/cid/ciu748. Epub 2014 Sep 30.
- Mandalakas AM, Hesseling AC, Gie RP, Schaaf HS, Marais BJ, Sinanovic E. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting. Thorax. 2013 Mar;68(3):247-55. doi: 10.1136/thoraxjnl-2011-200933. Epub 2012 Jun 20.
- Szkwarko D, Hirsch-Moverman Y, Du Plessis L, Du Preez K, Carr C, Mandalakas AM. Child contact management in high tuberculosis burden countries: A mixed-methods systematic review. PLoS One. 2017 Aug 1;12(8):e0182185. doi: 10.1371/journal.pone.0182185. eCollection 2017.
- Graham SM. The management of infection with Mycobacterium tuberculosis in young children post-2015: an opportunity to close the policy-practice gap. Expert Rev Respir Med. 2017 Jan;11(1):41-49. doi: 10.1080/17476348.2016.1267572. Epub 2016 Dec 10.
- Egere U, Sillah A, Togun T, Kandeh S, Cole F, Jallow A, Able-Thomas A, Hoelscher M, Heinrich N, Hill PC, Kampmann B. Isoniazid preventive treatment among child contacts of adults with smear-positive tuberculosis in The Gambia. Public Health Action. 2016 Dec 21;6(4):226-231. doi: 10.5588/pha.16.0073.
- Vasiliu A, Tiendrebeogo G, Awolu MM, Akatukwasa C, Tchakounte BY, Ssekyanzi B, Tchounga BK, Atwine D, Casenghi M, Bonnet M; CONTACT study group. Feasibility of a randomized clinical trial evaluating a community intervention for household tuberculosis child contact management in Cameroon and Uganda. Pilot Feasibility Stud. 2022 Feb 11;8(1):39. doi: 10.1186/s40814-022-00996-3.
- Vasiliu A, Eymard-Duvernay S, Tchounga B, Atwine D, de Carvalho E, Ouedraogo S, Kakinda M, Tchendjou P, Turyahabwe S, Kuate AK, Tiendrebeogo G, Dodd PJ, Graham SM, Cohn J, Casenghi M, Bonnet M. Community intervention for child tuberculosis active contact investigation and management: study protocol for a parallel cluster randomized controlled trial. Trials. 2021 Mar 2;22(1):180. doi: 10.1186/s13063-021-05124-9.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EG0211
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Beijing Chest HospitalHuashan Hospital; National Medical Center for Infectious DiseasesNot yet recruitingTuberculosis | Drug-resistant Tuberculosis | Pulmonary Tuberculosis | Rifampicin Resistant TuberculosisChina
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Assistance Publique - Hôpitaux de ParisCompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone TuberculosisFrance
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
Huashan HospitalThe Hong Kong Polytechnic UniversityNot yet recruitingPulmonary Tuberculosis | Tuberculosis (TB) | Tuberculosis ActiveChina
-
Shandong UniversityShandong Public Health Clinical CenterNot yet recruiting
-
Huashan HospitalBeijing Chest HospitalActive, not recruitingDrug-resistant Tuberculosis | Pulmonary Tuberculosis | Rifampin-resistant TuberculosisChina
Clinical Trials on Screening and initiating preventive therapy in communities
-
University of SunderlandUniversity of GlasgowNot yet recruitingCervical Cancer | Breast Cancer | Bowel Cancer | Abdominal Aortic AneurysmUnited Kingdom
-
Stanford UniversityBill and Melinda Gates Foundation; Instituto Nacional de Salud Publica, MexicoCompleted
-
Marche Region Regional Health AgencyREGIONAL HEALTH UNIT - MARCHE REGION - AREA 5 (ASUR Marche, Area Vasta 5,... and other collaboratorsNot yet recruitingCardiovascular Diseases | Diabetes Mellitus Type 2
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI)Not yet recruitingHIV Infections | Cervix Cancer | HPV InfectionZimbabwe
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institute on Minority Health and...RecruitingHIV Infections | Cervix Cancer | HPV InfectionUganda
-
ANRS, Emerging Infectious DiseasesCompletedMother to Child HIV TransmissionGuinea
-
Tampere UniversityEuropean Union; Academy of Finland; Cancer Society of FinlandActive, not recruitingCervical Intraepithelial Neoplasia Grade 2/3Finland
-
Africa Mental Health FoundationUniversity of British Columbia; Grand Challenges Canada; Nextgenu.org; CliniX Healthcare... and other collaboratorsCompletedSubstance-Related Disorders | Alcohol-Related Disorders | Social StigmaKenya
-
Ana Catarina Navarro RamalhoActive, not recruitingDepression | Anxiety | Chronic Musculoskeletal PainBelgium
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)Not yet recruitingYoung Adult-Mediated Intervention to Increase Colorectal Cancer ScreeningUnited States